Pfizer (PFE) AI Stock Analysis

• Market Cap: $144.87B
• Dividend Yield: 6.65%
• Average Volume (3M): 43.16M
• Price to Earnings (P/E): 14.9
• Beta (1Y): 0.41
• Revenue Growth: 4.44%
• EPS Growth: 128.96%
• Country: US
• Employees: 81,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.87
• Shares Outstanding: 5,685,707,500
• 10 Day Avg. Volume: 34,686,440
• 30 Day Avg. Volume: 43,159,282
• PEG Ratio: 0.07
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 2.36
• P/FCF Ratio: 15.28
• Enterprise Value/Market Cap: 1.26
• Enterprise Value/Revenue: 2.91
• Enterprise Value/Gross Profit: 4.09
• Enterprise Value/Ebitda: 8.63
• 1Y Price Target: $28.56
• Price Target Upside: 12.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: $29.00 ▲(14.67% Upside)

Pfizer's overall stock score reflects strong technical momentum and a solid valuation with an attractive dividend yield. Financial performance is stable but faces challenges in revenue growth and profitability. The earnings call provided positive guidance and strategic initiatives, though declining COVID-19 revenues and legal challenges with the Metsera acquisition pose risks. Overall, Pfizer is positioned well for long-term growth, but short-term challenges remain.

Positive Factors

Strategic Partnerships

This partnership enhances Pfizer's pipeline in chronic weight management, expanding its market presence and potential revenue streams.

R&D Pipeline

A robust R&D pipeline ensures long-term growth through innovation and new product offerings, maintaining competitive advantage.

Regulatory Advantage

Reduced trial requirements could accelerate Pfizer's product approvals, lowering costs and speeding up time-to-market for new drugs.

Negative Factors

Decline in COVID-19 Revenue

Decreased demand for COVID-19 products impacts overall revenue, challenging Pfizer to offset declines with other product lines.

Legal Challenges

Legal issues with acquisitions can delay strategic initiatives and create financial uncertainties, affecting long-term growth plans.

Cash Flow Decline

Declining cash flow limits Pfizer's ability to invest in growth opportunities and return capital to shareholders, impacting financial flexibility.

Pfizer Business Overview & Revenue Model

Company Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

How the Company Makes Money

Pfizer primarily generates revenue through the sale of prescription pharmaceuticals and vaccines. The company’s revenue model is supported by a diverse range of products across multiple therapeutic areas, allowing it to capitalize on various market segments. Key revenue streams include sales of patented drugs, which often command higher prices until they face generic competition, and sales of vaccines, particularly during public health emergencies or vaccination campaigns. Significant partnerships, such as the collaboration with BioNTech for the development of the COVID-19 vaccine, have also contributed to Pfizer's earnings, enhancing its market share and expanding its product offerings. Additionally, Pfizer invests heavily in research and development to innovate and bring new therapies to market, which further drives revenue growth.

Pfizer Financial Statement Overview

Summary

Pfizer demonstrates strong profitability and operational efficiency, with healthy EBIT and EBITDA margins. However, it faces challenges with declining revenue and free cash flow. The balance sheet is stable with moderate leverage, but the negative growth trends in revenue and cash flow could pose risks if not addressed.

Income Statement

Pfizer's income statement shows strong gross and net profit margins, with a TTM gross profit margin of 75.89% and net profit margin of 15.66%. However, the revenue growth rate is negative at -1.64% TTM, indicating a decline in sales. Despite this, the EBIT and EBITDA margins remain healthy, suggesting operational efficiency.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.66 TTM, indicating manageable leverage. The return on equity is 10.92% TTM, showing decent profitability. However, the equity ratio is not provided, which limits a full assessment of financial stability.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth at -16.58% TTM, which is a concern. The operating cash flow to net income ratio is 0.36, indicating reasonable cash generation relative to net income. The free cash flow to net income ratio is 0.79, suggesting that a significant portion of earnings is converted to free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.78B	63.63B	59.55B	100.33B	81.29B	41.65B
Gross Profit	44.70B	41.85B	30.34B	62.09B	46.88B	29.88B
EBITDA	21.17B	18.13B	9.56B	41.03B	30.79B	13.17B
Net Income	9.82B	8.02B	2.13B	31.36B	22.15B	9.16B
Balance Sheet
Total Assets	208.73B	213.40B	226.50B	197.21B	181.48B	154.23B
Cash, Cash Equivalents and Short-Term Investments	14.98B	20.48B	12.69B	22.73B	31.07B	12.22B
Total Debt	61.71B	66.99B	70.84B	34.86B	37.00B	38.27B
Total Liabilities	115.64B	124.90B	137.21B	101.29B	104.01B	90.76B
Stockholders Equity	92.80B	88.20B	89.01B	95.66B	77.20B	63.24B
Cash Flow
Free Cash Flow	10.38B	9.84B	4.79B	26.03B	29.87B	11.61B
Operating Cash Flow	13.08B	12.74B	8.70B	29.27B	32.58B	14.40B
Investing Cash Flow	3.17B	2.65B	-32.28B	-15.78B	-22.55B	-4.27B
Financing Cash Flow	-16.01B	-17.14B	26.07B	-14.83B	-9.82B	-9.65B

Pfizer Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Positive. The current price of 25.29 is above the 20-day moving average (MA) of 25.26, above the 50-day MA of 25.18, and above the 200-day MA of 23.91, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 43.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PFE.

Pfizer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	80 Outperform	$274.34B	14.62	39.51%	3.12%	1.59%	58.02%
NVS	80 Outperform	$272.03B	19.17	32.93%	2.87%	11.53%	-15.21%
JNJ	78 Outperform	$492.44B	19.73	33.62%	2.50%	5.08%	71.07%
AMGN	77 Outperform	$175.60B	25.21	81.71%	3.00%	11.03%	65.22%
PFE	74 Outperform	$144.87B	14.85	10.59%	6.65%	4.44%	128.96%
ABBV	66 Neutral	$388.97B	166.06	138.53%	2.87%	7.40%	-53.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Pfizer Corporate Events

Pfizer Revises 2025 Revenue Guidance to $62 Billion

On December 16, 2025, Pfizer announced its financial guidance for the full year 2026, while revising its 2025 revenue guidance to approximately $62.0 billion. The company expects 2026 revenues to range between $59.5 and $62.5 billion, with a decrease in COVID-19 product revenues and impacts from loss of exclusivity on certain products. Pfizer anticipates continued investment in its pipeline and acquired assets to fuel long-term growth, with adjusted diluted EPS for 2026 projected between $2.80 and $3.00. The financial outlook reflects Pfizer’s strategic focus on innovative medicines and vaccines, aiming to create long-term value for shareholders.

The most recent analyst rating on (PFE) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.

Pfizer Completes $5 Billion Public Offering

On November 21, 2025, Pfizer Inc. completed a significant public offering of various notes totaling $5 billion, with maturities ranging from 2027 to 2065. This financial move, conducted under a shelf registration statement, involved major financial institutions as underwriters and is expected to impact Pfizer’s financial strategy and market positioning.

The most recent analyst rating on (PFE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.

Pfizer Completes Acquisition of Metsera for $7 Billion

On November 13, 2025, Pfizer completed its acquisition of Metsera, Inc., a Delaware-based company, for approximately $7.0 billion. The acquisition includes contingent value rights for additional payments tied to the achievement of specific milestones related to Metsera’s GLP-1 receptor antagonist and amylin analog therapies, potentially impacting Pfizer’s strategic positioning in the pharmaceutical industry.

The most recent analyst rating on (PFE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.